IRIS Accounts Production v25.2.0.378 NI039068 Board of Directors Board of Directors 31.1.25 1.2.24 31.1.25 31.1.25 the provision of recruitment and employment services within the healthcare sector. true true false true true false false true false Ordinary Shares 0 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh NI039068 2024-01-31 NI039068 2025-01-31 NI039068 2024-02-01 2025-01-31 NI039068 2023-01-31 NI039068 2023-02-01 2024-01-31 NI039068 2024-01-31 NI039068 ns15:NorthernIreland 2024-02-01 2025-01-31 NI039068 ns14:PoundSterling 2024-02-01 2025-01-31 NI039068 ns10:Director1 2024-02-01 2025-01-31 NI039068 ns10:Director2 2024-02-01 2025-01-31 NI039068 ns10:Consolidated 2025-01-31 NI039068 ns10:ConsolidatedGroupCompanyAccounts 2024-02-01 2025-01-31 NI039068 ns10:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 NI039068 ns10:FRS102 ns10:Consolidated 2024-02-01 2025-01-31 NI039068 ns10:Consolidated ns10:Audited 2024-02-01 2025-01-31 NI039068 ns10:LargeCompaniesRegimeForDirectorsReport 2024-02-01 2025-01-31 NI039068 ns10:LargeCompaniesRegimeForAccounts 2024-02-01 2025-01-31 NI039068 ns10:Consolidated ns10:LargeCompaniesRegimeForDirectorsReport 2024-02-01 2025-01-31 NI039068 ns10:Consolidated ns10:LargeCompaniesRegimeForAccounts 2024-02-01 2025-01-31 NI039068 ns10:FullAccounts 2024-02-01 2025-01-31 NI039068 ns10:OrdinaryShareClass1 2024-02-01 2025-01-31 NI039068 ns10:Consolidated 2024-02-01 2025-01-31 NI039068 ns10:CompanySecretary1 2024-02-01 2025-01-31 NI039068 ns10:RegisteredOffice 2024-02-01 2025-01-31 NI039068 ns10:Consolidated 2023-02-01 2024-01-31 NI039068 ns5:CurrentFinancialInstruments 2025-01-31 NI039068 ns5:CurrentFinancialInstruments 2024-01-31 NI039068 ns5:ShareCapital 2025-01-31 NI039068 ns5:ShareCapital 2024-01-31 NI039068 ns5:RetainedEarningsAccumulatedLosses 2025-01-31 NI039068 ns5:RetainedEarningsAccumulatedLosses 2024-01-31 NI039068 ns5:ShareCapital 2023-01-31 NI039068 ns5:RetainedEarningsAccumulatedLosses 2023-01-31 NI039068 ns5:RetainedEarningsAccumulatedLosses 2023-02-01 2024-01-31 NI039068 ns5:RetainedEarningsAccumulatedLosses 2024-02-01 2025-01-31 NI039068 1 2024-02-01 2025-01-31 NI039068 1 2023-02-01 2024-01-31 NI039068 2 2024-02-01 2025-01-31 NI039068 2 2023-02-01 2024-01-31 NI039068 ns5:OwnedOrFreeholdAssets ns5:LandBuildings 2024-02-01 2025-01-31 NI039068 ns5:FurnitureFittings 2024-02-01 2025-01-31 NI039068 ns5:MotorVehicles 2024-02-01 2025-01-31 NI039068 ns5:ComputerEquipment 2024-02-01 2025-01-31 NI039068 ns5:LandBuildings 2024-01-31 NI039068 ns5:FurnitureFittings 2024-01-31 NI039068 ns5:MotorVehicles 2024-01-31 NI039068 ns5:ComputerEquipment 2024-01-31 NI039068 ns5:LandBuildings 2024-02-01 2025-01-31 NI039068 ns5:LandBuildings 2025-01-31 NI039068 ns5:FurnitureFittings 2025-01-31 NI039068 ns5:MotorVehicles 2025-01-31 NI039068 ns5:ComputerEquipment 2025-01-31 NI039068 ns5:LandBuildings 2024-01-31 NI039068 ns5:FurnitureFittings 2024-01-31 NI039068 ns5:MotorVehicles 2024-01-31 NI039068 ns5:ComputerEquipment 2024-01-31 NI039068 ns5:CostValuation 2024-01-31 NI039068 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-01-31 NI039068 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-01-31 NI039068 ns10:OrdinaryShareClass1 2025-01-31 NI039068 ns5:RetainedEarningsAccumulatedLosses 2024-01-31

REGISTERED NUMBER: NI039068 (Northern Ireland)

Group Strategic Report,

Report of the Directors and

Audited

Consolidated Financial Statements

for the Year Ended 31 January 2025

for

Direct Medics Ltd

| Direct Medics Ltd (Registered number: NI039068) |

Contents of the Consolidated Financial Statements

for the Year Ended 31 January 2025

Page |

| Company Information | 1 |

| Group Strategic Report | 2 |

| Report of the Directors | 4 |

| Statement of Directors' Responsibilities | 6 |

| Report of the Independent Auditors | 7 |

| Consolidated Income Statement | 11 |

| Consolidated Other Comprehensive Income | 12 |

| Consolidated Balance Sheet | 13 |

| Company Balance Sheet | 14 |

| Consolidated Statement of Changes in Equity | 15 |

| Company Statement of Changes in Equity | 16 |

| Consolidated Cash Flow Statement | 17 |

| Company Cash Flow Statement | 18 |

| Notes to the Cash Flow Statements | 19 |

| Notes to the Consolidated Financial Statements | 21 |

| Direct Medics Ltd |

Company Information

for the Year Ended 31 January 2025

| DIRECTORS: | A Flannery

| P O Mulvenna

| SECRETARY: | P O Mulvenna

| REGISTERED OFFICE: | Unit 6A

| Hawthorne Office Park

| 33a Stockmans Way

| Belfast

| BT9 7ET

| REGISTERED NUMBER: | NI039068 (Northern Ireland)

| INDEPENDENT AUDITORS: | M.B.Mc Grady & Co

| Chartered Accountants

| Statutory Auditors

| Rathmore House

| 52 St Patricks Avenue

| Downpatrick

| Co. Down

| BT30 6DS

| SOLICITORS: | McCartan Turkington Breen

| Northern Court

| 16-18 Gloucester Street

| Belfast

| Northern Ireland

| BT1 4LS

| Direct Medics Ltd (Registered number: NI039068) |

Group Strategic Report

for the Year Ended 31 January 2025

The directors present their strategic report of the company and the group for the year ended 31 January 2025.

PRINCIPAL RISKS AND UNCERTAINTIES

Operating risks

The market for healthcare recruitment services remains highly competitive in the current economic climate. The directors are confident that appropriate steps have been taken to ensure the company is competitive in future years. The company seeks to manage the risk of losing customers to key competitors by providing a high value service and by maintaining strong relationships and local representation with key customers.

Credit risk

The company views credit risk as an important focus in our day-to-day activities, especially in the current economic climate. Our approach to mitigate this risk is to operate a dedicated credit control team who monitor risk throughout the sales process and closely manage overdue amounts.

Currency risk

The group's objective in relation to currency risk is to minimize the exposure to foreign exchange losses. Only one of the companies within the group trades in a foreign currency and this is Euro-denominated. As such currency risk is low and not significant to the performance of the group. The company's activity exposes it to credit and liquidity risks. The company's credit risk relates to its trade debtors. The company manages this risk through regular reviews of outstanding balances and performing credit checks and maintaining trade credit insurance.

The company seeks to manage financial risks to ensure sufficient liquidity is available to meet foreseeable needs and to invest cash assets safely and profitably. Short term flexibility is achieved by means of advances from other group undertakings.

| Direct Medics Ltd (Registered number: NI039068) |

Group Strategic Report

for the Year Ended 31 January 2025

SECTION 172(1) STATEMENT

From the perspective of the Directors, the matters for consideration under section 172 of the Companies Act 2006 ("sl72") have been considered to an appropriate extent by the company. Such consideration is included in the statements set out below, noting the Directors' duty under s172 to act in good faith to promote the success of the company for the benefit of its shareholders but having regard amongst other matters to the following:

- the likely consequences of any decision in the long term;

- the interests of the company's employees;

- the need to foster the company's business relationships with customers and others;

- the impact of the company's operations on the community and the environment.

- the desirability of the company maintaining a reputation for high standards of business conduct; and

- the need to act fairly as between members of the company.

For the company, compliance is one of the cornerstone values and forms the basis for all decisions and activities. It is the key to integrity in conducting business. The Directors are committed to ensuring that all business is carried out in full accordance with the law as well as internal rules and principles.

The Board of Directors of the company, confirmed that they have acted in the way they consider, in good faith, would be most likely to promote success of the company for the benefit of its members as a whole (having regard to the stakeholders and matters set out in Section 172(1) (a-f) of the Act) in the decisions taken during the year ended 31 January 2024. The following paragraphs summarise how the directors fulfil their duties:

- As the board of directors, the directors' intention is to behave responsibly and ensure that management operate the business in a responsible manner.

- As the board of directors, the directors are committed to openly engage with the company's shareholders. It is important to the Directors that shareholders understand the company's strategy and objectives, so these must be clearly communicated, feedback heard, and issues or questions raised properly considered.

- As the company's services provided grow, the directors' risk environment also becomes more complex. It is, therefore, important that the directors effectively identify, evaluate, manage and mitigate the risks the company faces. For details of the company's principal risks and uncertainties, please see previous paragraphs of our company strategic report.

- The company's employees are vital to the services provided by the company. The company aims to be a responsible employer in its approach to the pay and benefits for its employees. For the business to succeed, the company needs to manage its employees' performance and develop talent while ensuring the company operates as efficiently as possible. The health and safety of the company's employees is very important to the company.

- In order to grow the business, the company needs to develop and maintain strong business relationships. The company values all of its suppliers and customers.

ON BEHALF OF THE BOARD:

P O Mulvenna - Director

16 October 2025

| Direct Medics Ltd (Registered number: NI039068) |

Report of the Directors

for the Year Ended 31 January 2025

The directors present their report with the financial statements of the company and the group for the year ended 31 January 2025.

DIVIDENDS

The profit before taxation amounted to £2.77m (financial year ended 31 January 2024: £2.36m).

The directors paid an interim dividend of £2,600,000 (2024: £1,180,000).

FUTURE DEVELOPMENTS

The directors and senior management team will continue to focus on cost control and operational efficiency over the coming financial year.

DIRECTORS

The directors shown below have held office during the whole of the period from 1 February 2024 to the date of this report.

A Flannery

P O Mulvenna

DISABLED EMPLOYEES

The company gives full consideration to applications for employment from disabled persons where the requirements of the job can be adequately fulfilled by a disabled person. Where existing employees become disabled, it is the company's policy wherever practicable to provide continuing employment under normal terms and conditions and to provide training and career development and promotion to disabled employees wherever appropriate.

EMPLOYEE MATTERS

The well-being of the company's employees is safeguarded through the strict adherence to health and safety standards. The company implements appropriate measures to ensure full compliance with the relevant legislation, including the adoption of a safety statement.

MAIN STAKEHOLDER OVERVIEW

The directors believe that identifying its key stakeholders and engaging them to understand their priorities helps to build long term value.

The company works with its main stakeholders as outlined below.

ENGAGEMENT WITH EMPLOYEES

Our employees are at the heart of everything we do, and it is essential that we build productive relationships, built on trust and respect. Our main focus is staff engagement which we believe is increased by ensuring there an environment which fosters continuous development. Development comes from our comprehensive approach to performance appraisal, including coaching, regular one-to-one discussions and the provision of training where beneficial.

We also provide regular opportunities for various teams within the business to get together, to hear from the senior team about our strategy, to share ideas, and to celebrate success.

We are also committed to providing comprehensive measures to ensure the health, safety and wellbeing of our employees and providing excellent health-related benefits to staff, incorporating both physical and mental health.

| Direct Medics Ltd (Registered number: NI039068) |

Report of the Directors

for the Year Ended 31 January 2025

ENGAGEMENT WITH SUPPLIERS, CUSTOMERS AND OTHERS

Customers

Understanding our customers' needs is critical to the success of our business. We engage with all our customers regularly through a variety of channels, including face to face meetings, formal performance reviews, workshops and seminars.

Suppliers

Excellent ongoing relationships with our suppliers help us to ensure that we provide our services effectively and to a high standard. In this respect we are working hard to rationalise our suppliers, resulting in a reliable, tried and tested supplier base who help us ensure we deliver for our customers.

Community and environment

The company's operations are at the very heart of our local communities where our customers and employees work. We are proud of our ongoing efforts to provided sustained economic benefits and prosperity across the UK and Ireland.

STREAMLINED ENERGY AND CARBON REPORTING

As the group has not consumed more than 40,000kWh of energy in this reporting period, it qualified as a low energy user under these regulations and is not required to report on its emissions, energy consumption or energy efficiency activities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

AUDITORS

The auditors, M.B.Mc Grady & Co, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:

P O Mulvenna - Director

16 October 2025

| Direct Medics Ltd (Registered number: NI039068) |

Statement of Directors' Responsibilities

for the Year Ended 31 January 2025

The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- | select suitable accounting policies and then apply them consistently;

- | make judgements and accounting estimates that are reasonable and prudent;

- | state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;

- | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Report of the Independent Auditors to the Members of

Direct Medics Ltd

Opinion

We have audited the financial statements of Direct Medics Ltd (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 January 2025 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement, Company Cash Flow Statement and Notes to the Cash Flow Statements, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- | give a true and fair view of the state of the group's and of the parent company affairs as at 31 January 2025 and of the group's profit for the year then ended;

- | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- | have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report, the Report of the Directors and the Statement of Directors' Responsibilities, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Report of the Independent Auditors to the Members of

Direct Medics Ltd

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- | the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and

- | the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- | adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or

- | the parent company financial statements are not in agreement with the accounting records and returns; or

- | certain disclosures of directors' remuneration specified by law are not made; or

- | we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page six, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of

Direct Medics Ltd

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. In assessing and detecting irregularities such as fraud and non-compliance with laws and regulations we considered the following:

- the matters discussed among the audit engagement team and any other relevant professionals regarding how and where fraud might occur in the financial statements and any potential indicators of fraud;

- the nature of the industry and any laws and regulations applicable to the company and the industry;

- the company's own assessment of the risk of fraud and other irregularities;

- the company's policies and procedures in relation to:

- how they identify and comply with all relevant laws and regulations and whether they are aware of any non-compliance;

- how they detect and respond to risks of fraud and their knowledge of any actual, suspected or alleged fraud; and

- the control environment within the company and how this mitigates risks of fraud and instances of

non-compliance with laws and regulations.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in relation to misappropriation of assets. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

In response to the risk of material misstatement through irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- ensuring the engagement team had the appropriate knowledge and expertise in order to be able to identify and recognise any instances of fraud or non-compliance with laws and regulations;

- we identified the laws and regulations applicable to the company through discussions with directors and management and from our knowledge and experience of the sector; and

- ensuring the audit was carried out with a level of professional scepticism.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- enquiring of management concerns of actual and potential litigation and claims;

- agreeing the financial statement disclosures to underlying supporting documentation to assess compliance with relevant laws and regulations; and

- reviewing correspondence with HMRC and other relevant regulators and the company's legal advisors.

To address the risk of fraud through management bias and override of controls, we:

- perform analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;

- test the appropriateness of journal entries and other adjustments;

- assess whether the judgements made in making accounting estimates are indicative of a potential bias; and

- evaluate the business rationale of any significant transactions that are unusual or outside the normal course of business.

Report of the Independent Auditors to the Members of

Direct Medics Ltd

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and significant component audit teams, and remained alert to any indications of fraud or noncompliance with laws and regulations throughout the audit.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Malachy McGrady FCA (Senior Statutory Auditor)

for and on behalf of M.B.Mc Grady & Co

Chartered Accountants

Statutory Auditors

Rathmore House

52 St Patricks Avenue

Downpatrick

Co. Down

BT30 6DS

16 October 2025

| Direct Medics Ltd (Registered number: NI039068) |

Consolidated

Income Statement

for the Year Ended 31 January 2025

| 31/1/25 |  | 31/1/24

| Notes | £ | £ |

TURNOVER | 77,460,580 |  | 84,284,200 |  |

Cost of sales | (68,395,641 | ) | (75,772,604 | ) |

GROSS PROFIT | 9,064,939 |  | 8,511,596 |  |

Administrative expenses | (6,098,986 | ) | (5,758,896 | ) |

2,965,953 |  | 2,752,700 |  |

Other operating income | 39,334 |  | 16,944 |  |

OPERATING PROFIT | 4 | 3,005,287 |  | 2,769,644 |  |

Interest receivable and similar income | 45,426 |  | 1,557 |  |

3,050,713 |  | 2,771,201 |  |

Interest payable and similar expenses | 5 | (27,385 | ) | (196,820 | ) |

PROFIT BEFORE TAXATION | 3,023,328 |  | 2,574,381 |  |

Tax on profit | 6 | (755,867 | ) | (634,763 | ) |

PROFIT FOR THE FINANCIAL YEAR | 2,267,461 |  | 1,939,618 |  |

Profit attributable to:

Owners of the parent | 2,267,461 |  | 1,939,618 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Consolidated

Other Comprehensive Income

for the Year Ended 31 January 2025

| 31/1/25 |  | 31/1/24

| Notes | £ | £ |

PROFIT FOR THE YEAR | 2,267,461 |  | 1,939,618 |  |

OTHER COMPREHENSIVE INCOME | - |  | - |  |

TOTAL COMPREHENSIVE INCOME FOR THE YEAR | 2,267,461 |  | 1,939,618 |  |

Total comprehensive income attributable to:

Owners of the parent | 2,267,461 |  | 1,939,618 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Consolidated Balance Sheet

31 January 2025

| 31/1/25 | 31/1/24 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 9 | 434,561 |  | 449,221 |  |

Investments | 10 | - |  | - |  |

434,561 |  | 449,221 |  |

CURRENT ASSETS

Debtors | 11 | 16,392,526 |  | 25,395,614 |  |

Cash at bank and in hand | 3,046,710 |  | 568,508 |  |

19,439,236 |  | 25,964,122 |  |

CREDITORS

Amounts falling due within one year | 12 | 9,246,371 |  | 15,453,378 |  |

NET CURRENT ASSETS | 10,192,865 |  | 10,510,744 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 10,627,426 |  | 10,959,965 |  |

CAPITAL AND RESERVES

Called up share capital | 14 | 2 |  | 2 |  |

Retained earnings | 15 | 10,627,424 |  | 10,959,963 |  |

SHAREHOLDERS' FUNDS | 10,627,426 |  | 10,959,965 |  |

The financial statements were approved by the Board of Directors and authorised for issue on 16 October 2025 and were signed on its behalf by:

P O Mulvenna - Director

A Flannery - Director

| Direct Medics Ltd (Registered number: NI039068) |

Company Balance Sheet

31 January 2025

| 31/1/25 | 31/1/24 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 9 | 434,563 |  | 449,223 |  |

Investments | 10 | 183 |  | 183 |  |

434,746 |  | 449,406 |  |

CURRENT ASSETS

Debtors | 11 | 15,584,493 |  | 24,296,462 |  |

Cash at bank and in hand | 2,501,591 |  | 374,954 |  |

18,086,084 |  | 24,671,416 |  |

CREDITORS

Amounts falling due within one year | 12 | 8,911,248 |  | 15,015,180 |  |

NET CURRENT ASSETS | 9,174,836 |  | 9,656,236 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 9,609,582 |  | 10,105,642 |  |

CAPITAL AND RESERVES

Called up share capital | 14 | 2 |  | 2 |  |

Retained earnings | 15 | 9,609,580 |  | 10,105,640 |  |

SHAREHOLDERS' FUNDS | 9,609,582 |  | 10,105,642 |  |

Company's profit for the financial year | 2,103,940 |  | 1,794,182 |  |

The financial statements were approved by the Board of Directors and authorised for issue on 16 October 2025 and were signed on its behalf by:

P O Mulvenna - Director

A Flannery - Director

| Direct Medics Ltd (Registered number: NI039068) |

Consolidated Statement of Changes in Equity

for the Year Ended 31 January 2025

| Called up |

| share |  | Retained |  | Total

| capital |  | earnings |  | equity

£ | £ | £ |

Balance at 1 February 2023 | 2 |  | 10,200,345 |  | 10,200,347 |  |

Changes in equity

Dividends | - |  | (1,180,000 | ) | (1,180,000 | ) |

Total comprehensive income | - |  | 1,939,618 |  | 1,939,618 |  |

Balance at 31 January 2024 | 2 |  | 10,959,963 |  | 10,959,965 |  |

Changes in equity

Dividends | - |  | (2,600,000 | ) | (2,600,000 | ) |

Total comprehensive income | - |  | 2,267,461 |  | 2,267,461 |  |

Balance at 31 January 2025 | 2 |  | 10,627,424 |  | 10,627,426 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Company Statement of Changes in Equity

for the Year Ended 31 January 2025

| Called up |

| share |  | Retained |  | Total

| capital |  | earnings |  | equity

£ | £ | £ |

Balance at 1 February 2023 | 2 |  | 9,491,458 |  | 9,491,460 |  |

Changes in equity

Dividends | - |  | (1,180,000 | ) | (1,180,000 | ) |

Total comprehensive income | - |  | 1,794,182 |  | 1,794,182 |  |

Balance at 31 January 2024 | 2 |  | 10,105,640 |  | 10,105,642 |  |

Changes in equity

Dividends | - |  | (2,600,000 | ) | (2,600,000 | ) |

Total comprehensive income | - |  | 2,103,940 |  | 2,103,940 |  |

Balance at 31 January 2025 | 2 |  | 9,609,580 |  | 9,609,582 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Consolidated Cash Flow Statement

for the Year Ended 31 January 2025

| 31/1/25 |  | 31/1/24

| Notes | £ | £ |

Cash flows from operating activities

Cash generated from operations | 1 | 6,884,352 |  | 560,437 |  |

Interest paid | (27,385 | ) | (196,820 | ) |

Tax paid | (423,473 | ) | (378,027 | ) |

Net cash from operating activities | 6,433,494 |  | (14,410 | ) |

Cash flows from investing activities

Purchase of tangible fixed assets | (19,718 | ) | (32,878 | ) |

Interest received | 45,426 |  | 1,557 |  |

Net cash from investing activities | 25,708 |  | (31,321 | ) |

Cash flows from financing activities

New loans in year | - |  | 361,000 |  |

Loan repayments in year | (361,000 | ) | - |  |

Amount introduced by directors | 3,460,324 |  | 4,205,324 |  |

Amount withdrawn by directors | (4,480,324 | ) | (3,460,324 | ) |

Equity dividends paid | (2,600,000 | ) | (1,180,000 | ) |

Net cash from financing activities | (3,981,000 | ) | (74,000 | ) |

Increase/(decrease) in cash and cash equivalents | 2,478,202 |  | (119,731 | ) |

Cash and cash equivalents at beginning of year | 2 | 568,508 |  | 688,239 |  |

Cash and cash equivalents at end of year | 2 | 3,046,710 |  | 568,508 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Company Cash Flow Statement

for the Year Ended 31 January 2025

| 31/1/25 |  | 31/1/24

| Notes | £ | £ |

Cash flows from operating activities

Cash generated from operations | 1 | 6,534,333 |  | 659,361 |  |

Interest paid | (27,131 | ) | (196,546 | ) |

Finance income | - |  | (12,098 | ) |

Tax paid | (403,971 | ) | (378,000 | ) |

Net cash from operating activities | 6,103,231 |  | 72,717 |  |

Cash flows from investing activities

Purchase of tangible fixed assets | (19,718 | ) | (32,879 | ) |

Interest received | 41,687 |  | 12,098 |  |

Net cash from investing activities | 21,969 |  | (20,781 | ) |

Cash flows from financing activities

New loans in year | - |  | 361,000 |  |

Loan repayments in year | (361,000 | ) | - |  |

Amount introduced by directors | 3,460,324 |  | 4,205,324 |  |

Amount withdrawn by directors | (4,480,324 | ) | (3,460,324 | ) |

Payments made on behalf of subsidiaries | (25,098 | ) | 84,651 |  |

Payments made by subsidiaries for parent | 7,535 |  | - |  |

Equity dividends paid | (2,600,000 | ) | (1,180,000 | ) |

Net cash from financing activities | (3,998,563 | ) | 10,651 |  |

Increase in cash and cash equivalents | 2,126,637 |  | 62,587 |  |

Cash and cash equivalents at beginning of year | 2 | 374,954 |  | 312,367 |  |

Cash and cash equivalents at end of year | 2 | 2,501,591 |  | 374,954 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Cash Flow Statements

for the Year Ended 31 January 2025

1. | RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

| Group

| 31/1/25 |  | 31/1/24

£ | £ |

| Profit before taxation | 3,023,328 |  | 2,574,381 |  |

| Depreciation charges | 34,378 |  | 30,435 |  |

| Finance costs | 27,385 |  | 196,820 |  |

| Finance income | (45,426 | ) | (1,557 | ) |

3,039,665 |  | 2,800,079 |  |

| Decrease/(increase) in trade and other debtors | 9,003,088 |  | (6,387,918 | ) |

| (Decrease)/increase in trade and other creditors | (5,158,401 | ) | 4,148,276 |  |

| Cash generated from operations | 6,884,352 |  | 560,437 |  |

| Company

| 31/1/25 |  | 31/1/24

£ | £ |

| Profit before taxation | 2,810,140 |  | 2,360,929 |  |

| Depreciation charges | 34,378 |  | 30,435 |  |

| Finance costs | 27,131 |  | 196,546 |  |

| Finance income | (41,687 | ) | - |  |

2,829,962 |  | 2,587,910 |  |

| Decrease/(increase) in trade and other debtors | 8,717,785 |  | (5,979,615 | ) |

| (Decrease)/increase in trade and other creditors | (5,013,414 | ) | 4,051,066 |  |

| Cash generated from operations | 6,534,333 |  | 659,361 |  |

2. | CASH AND CASH EQUIVALENTS

| The amounts disclosed on the Cash Flow Statements in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

| Group |  | Company |

| Year ended 31 January 2025

| 31/1/25 |  | 1/2/24 |  | 31/1/25 |  | 1/2/24

£ | £ | £ | £ |

| Cash and cash equivalents | 3,046,710 |  | 568,508 |  | 2,501,591 |  | 374,954 |  |

| Year ended 31 January 2024

| 31/1/24 |  | 1/2/23 |  | 31/1/24 |  | 1/2/23

£ | £ | £ | £ |

| Cash and cash equivalents | 568,508 |  | 688,239 |  | 374,954 |  | 312,367 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Cash Flow Statements

for the Year Ended 31 January 2025

3. | ANALYSIS OF CHANGES IN NET FUNDS

| Group

| At 1/2/24 | Cash flow | At 31/1/25

£ | £ | £ |

| Net cash |

| Cash at bank and in hand | 568,508 |  | 2,478,202 |  | 3,046,710 |  |

568,508 |  | 2,478,202 |  | 3,046,710 |  |

| Debt

| Debts falling due within 1 year | (361,000 | ) | 361,000 |  | - |  |

(361,000 | ) | 361,000 |  | - |  |

| Total | 207,508 |  | 2,839,202 |  | 3,046,710 |  |

| Company

| At 1/2/24 | Cash flow | At 31/1/25

£ | £ | £ |

| Net cash |

| Cash at bank and in hand | 374,954 |  | 2,126,637 |  | 2,501,591 |  |

374,954 |  | 2,126,637 |  | 2,501,591 |  |

| Debt

| Debts falling due within 1 year | (361,000 | ) | 361,000 |  | - |  |

(361,000 | ) | 361,000 |  | - |  |

| Total | 13,954 |  | 2,487,637 |  | 2,501,591 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Consolidated Financial Statements

for the Year Ended 31 January 2025

1. | STATUTORY INFORMATION

| Direct Medics Ltd is a private company, limited by shares , registered in Northern Ireland. The company's registered number and registered office address can be found on the General Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| The financial statemens are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Consolidated Financial Statements - continued

for the Year Ended 31 January 2025

2. | ACCOUNTING POLICIES - continued

| Basis of consolidation

| In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probably and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition fate. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.

| Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.

| The consolidated group financial statements consist of the financial statements of the parent company Direct Medics Limited together with all entities controlled by the parent company (its subsidiaries) and the group's share of its interests in joint ventures and associates.

| All financial statements are made up to 31 January 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

| All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

| Medistaff Locum Recruitment Limited and Career Locum Group Limited has been included in the group financial statements using the purchase method of accounting. Accordingly, the group profit and loss account and statement of cash flows include the results and cash flows of Medistaff Locum Recruitment Limited and Career Locum Group Limited for the year.

| Entities in which the group holds an interest and which are jointly controlled by the group and one or more other venturers under a contractual arrangement are treated as joint ventures. Entities other than subsidiary undertakings or joint ventures, in which the group has a participating interest and over whose operating and financial policies the group exercises a significant influences, are treated as associates.

| Investments in joint ventures and associates are carried in the group balance sheet at cost plus post-acquisition changes in the group's share of the net assets of the entity, less any impairment in value. The carrying values of investments in joint ventures and associates include acquired goodwill.

| If the group's share of losses in a joint venture of associate equals or exceeds its investment in the joint venture or associate, the group does not recognise further losses unless it has incurred obligations to do so or has made payments on behalf of the joint venture or associate.

| Unrealised gains arising from transactions with joint ventures and associates are eliminated to the extent of the group's interest in the entity.

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Consolidated Financial Statements - continued

for the Year Ended 31 January 2025

2. | ACCOUNTING POLICIES - continued

| Significant judgements and estimates

| Impairment of trade debtors

| In assessing impairment, management estimates the recoverable amount from each customer and estimation uncertainty relates to assumptions about future payment patterns based on factors such as historic payment trends and latest customer communications.

| Turnover

| Income from the provision of temporary contractors is recognised at the end of the completed working week based on hours worked multiplied by the contracted rate, net of rebates. There is deemed to be one performance obligation, being the satisfactory completion of the daily hours. Revenue is only recognised when the labour or service has been provided and the company is entitled to the revenue.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Freehold property | - | 2% on cost

| Fixtures and fittings | - | 20% on cost

| Motor vehicles | - | 20% on cost

| Computer equipment | - | 20% on cost

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Hire purchase and leasing commitments

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

| Pension costs and other post-retirement benefits

| The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate.

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Consolidated Financial Statements - continued

for the Year Ended 31 January 2025

2. | ACCOUNTING POLICIES - continued

| Debtors and creditors receivable / payable within one year

| Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.

| Impairment

| Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the asset’s cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

| Going concern

| The Directors have assessed the Group's ability to operate as a going concern based on the profits, reserves and cash flow forecasts arising from ongoing contractual obligations over the twelve months from the date of the signing of the accounts.

| Based on this assessment, the Directors have concluded that there is a reasonable expectation that the Group has adequate resources to continue to operate for the foreseeable future. The Group therefore continues to adopt the going concern basis in the preparation of its financial statements.

3. | EMPLOYEES AND DIRECTORS

| 31/1/25 |  | 31/1/24

£ | £ |

| Wages and salaries | 41,907,551 |  | 44,599,108 |  |

| Social security costs | 4,782,871 |  | 5,345,504 |  |

| Other pension costs | 570,115 |  | 596,429 |  |

47,260,537 |  | 50,541,041 |  |

| The average number of employees during the year was as follows:

| 31/1/25 |  | 31/1/24

| Medical and administration staff | 665 |  | 704 |  |

| 31/1/25 |  | 31/1/24

£ | £ |

| Directors' remuneration | 35,600 |  | 32,000 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Consolidated Financial Statements - continued

for the Year Ended 31 January 2025

4. | OPERATING PROFIT

| The operating profit is stated after charging:

| 31/1/25 |  | 31/1/24

£ | £ |

| Other operating leases | 86,137 |  | - |  |

| Depreciation - owned assets | 34,378 |  | 30,435 |  |

| Auditors' remuneration | 36,663 |  | 70,053 |  |

| Foreign exchange differences | 9,434 |  | 17,331 |  |

5. | INTEREST PAYABLE AND SIMILAR EXPENSES |

| 31/1/25 |  | 31/1/24

£ | £ |

| Bank interest | 27,385 |  | 190,428 |  |

| Interest payable | - |  | 6,392 |  |

27,385 |  | 196,820 |  |

6. | TAXATION

| Analysis of the tax charge

| The tax charge on the profit for the year was as follows:

| 31/1/25 |  | 31/1/24

£ | £ |

| Current tax:

| UK corporation tax | 755,867 |  | 634,763 |  |

| Tax on profit | 755,867 |  | 634,763 |  |

7. | INDIVIDUAL INCOME STATEMENT

| As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements.

8. | DIVIDENDS

| 31/1/25 |  | 31/1/24

£ | £ |

| Ordinary Shares shares of 1 each

| Final | 2,600,000 |  | 1,180,000 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Consolidated Financial Statements - continued

for the Year Ended 31 January 2025

9. | TANGIBLE FIXED ASSETS

| Group

| Fixtures |

| Freehold |  | and |  | Motor |  | Computer |

| property |  | fittings |  | vehicles |  | equipment |  | Totals

£ | £ | £ | £ | £ |

| COST

| At 1 February 2024 | 516,683 |  | 80,077 |  | 13,995 |  | 201,549 |  | 812,304 |  |

| Additions | - |  | - |  | - |  | 19,718 |  | 19,718 |  |

| At 31 January 2025 | 516,683 |  | 80,077 |  | 13,995 |  | 221,267 |  | 832,022 |  |

| DEPRECIATION

| At 1 February 2024 | 134,341 |  | 78,633 |  | 2,799 |  | 147,310 |  | 363,083 |  |

| Charge for year | 10,334 |  | 361 |  | 2,799 |  | 20,884 |  | 34,378 |  |

| At 31 January 2025 | 144,675 |  | 78,994 |  | 5,598 |  | 168,194 |  | 397,461 |  |

| NET BOOK VALUE

| At 31 January 2025 | 372,008 |  | 1,083 |  | 8,397 |  | 53,073 |  | 434,561 |  |

| At 31 January 2024 | 382,342 |  | 1,444 |  | 11,196 |  | 54,239 |  | 449,221 |  |

| Company

| Fixtures |

| Freehold |  | and |  | Motor |  | Computer |

| property |  | fittings |  | vehicles |  | equipment |  | Totals

£ | £ | £ | £ | £ |

| COST

| At 1 February 2024 | 516,683 |  | 80,078 |  | 13,995 |  | 201,549 |  | 812,305 |  |

| Additions | - |  | - |  | - |  | 19,718 |  | 19,718 |  |

| At 31 January 2025 | 516,683 |  | 80,078 |  | 13,995 |  | 221,267 |  | 832,023 |  |

| DEPRECIATION

| At 1 February 2024 | 134,340 |  | 78,633 |  | 2,799 |  | 147,310 |  | 363,082 |  |

| Charge for year | 10,334 |  | 361 |  | 2,799 |  | 20,884 |  | 34,378 |  |

| At 31 January 2025 | 144,674 |  | 78,994 |  | 5,598 |  | 168,194 |  | 397,460 |  |

| NET BOOK VALUE

| At 31 January 2025 | 372,009 |  | 1,084 |  | 8,397 |  | 53,073 |  | 434,563 |  |

| At 31 January 2024 | 382,343 |  | 1,445 |  | 11,196 |  | 54,239 |  | 449,223 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Consolidated Financial Statements - continued

for the Year Ended 31 January 2025

10. | FIXED ASSET INVESTMENTS

| Company

| Shares in

| group

| undertakings

£ |

| COST

| At 1 February 2024

| and 31 January 2025 | 183 |  |

| NET BOOK VALUE

| At 31 January 2025 | 183 |  |

| At 31 January 2024 | 183 |  |

| The group or the company's investments at the Balance Sheet date in the share capital of companies include the following:

| Subsidiaries

| Career Locum Group

| Registered office: England & Wales

| Nature of business: Recruitment

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| 31/1/25 |  | 31/1/24

£ | £ |

| Aggregate capital and reserves | 460,932 |  | 345,996 |  |

| Profit for the year | 114,936 |  | 119,047 |  |

| Medistaff Locum Recruitment

| Registered office: Republic of Ireland

| Nature of business: Recruitment

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| 31/1/25 |  | 31/1/24

£ | £ |

| Aggregate capital and reserves | 557,000 |  | 508,511 |  |

| Profit for the year | 48,489 |  | 196,923 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Consolidated Financial Statements - continued

for the Year Ended 31 January 2025

11. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| Group |  | Company |

| 31/1/25 |  | 31/1/24 |  | 31/1/25 |  | 31/1/24 |

£ | £ | £ | £ |

| Trade debtors | 13,411,566 |  | 22,243,752 |  | 12,707,105 |  | 21,316,574 |  |

| Amounts owed by group undertakings | - |  | - |  | 5,816 |  | - |  |

| Other debtors | 78,279 |  | 101,140 |  | 2,930 |  | 1,930 |  |

| Prepayments and accrued income | 2,902,681 |  | 3,050,722 |  | 2,868,642 |  | 2,977,958 |  |

16,392,526 |  | 25,395,614 |  | 15,584,493 |  | 24,296,462 |  |

12. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| Group |  | Company |

| 31/1/25 |  | 31/1/24 |  | 31/1/25 |  | 31/1/24 |

£ | £ | £ | £ |

| Other loans (see note 13) | - |  | 361,000 |  | - |  | 361,000 |  |

| Trade creditors | 51,480 |  | 1 |  | 51,479 |  | 2 |  |

| Amounts owed to group undertakings | - |  | - |  | 7,535 |  | 19,282 |  |

| Tax | 983,010 |  | 650,616 |  | 864,242 |  | 562,013 |  |

| Social security and other taxes | 1,496,975 |  | 3,883,832 |  | 1,444,759 |  | 3,791,084 |  |

| VAT | 902,089 |  | 2,799,958 |  | 836,463 |  | 2,673,388 |  |

| Other creditors | 124,889 |  | 370,357 |  | 56,183 |  | 352,737 |  |

| Directors' loan accounts | 3,185,324 |  | 4,205,324 |  | 3,185,324 |  | 4,205,324 |  |

| Accruals and deferred income | - |  | 95,704 |  | - |  | - |  |

| Accrued expenses | 2,502,604 |  | 3,086,586 |  | 2,465,263 |  | 3,050,350 |  |

9,246,371 |  | 15,453,378 |  | 8,911,248 |  | 15,015,180 |  |

13. | LOANS

| An analysis of the maturity of loans is given below:

| Group |  | Company |

| 31/1/25 |  | 31/1/24 |  | 31/1/25 |  | 31/1/24 |

£ | £ | £ | £ |

| Amounts falling due within one year or on | demand: |

| Other loans | - |  | 361,000 |  | - |  | 361,000 |  |

14. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 31/1/25 |  | 31/1/24

| value: | £ | £ |

| 2 | Ordinary Shares | 1 | 2 |  | 2 |  |

| Direct Medics Ltd (Registered number: NI039068) |

Notes to the Consolidated Financial Statements - continued

for the Year Ended 31 January 2025

15. | RESERVES

| Group

| Retained

| earnings

£ |

| At 1 February 2024 | 10,959,963 |  |

| Profit for the year | 2,267,461 |  |

| Dividends | (2,600,000 | ) |

| At 31 January 2025 | 10,627,424 |  |

| Company

| Retained

| earnings

£ |

| At 1 February 2024 | 10,105,640 |  |

| Profit for the year | 2,103,940 |  |

| Dividends | (2,600,000 | ) |

| At 31 January 2025 | 9,609,580 |  |

16. | RELATED PARTY DISCLOSURES

| The group was under the control of its directors during the year.

| At year end, the parent company Direct Medics Limited was owed £5,816 (2024: owed £19,282) by its subsidiary Career Locum Group Limited and owed £7,535 (2024: £nil) to its subsidiary Medistaff Locum Recruitment.

| With regard to the directors, they were owed £3,185,234 (2024: £4,205,324) at the year end in interest free loans.